Children with congenital heart disease require periodic neurodevelopmental surveillance and screening to identify deficits and facilitate early therapeutic interventions for improved long-term outcomes.
Answers are grounded in this paper and cite their sources.
Supports neurodevelopmental surveillance in congenital heart disease; leaves open optimal protocols and outcome benefits from prospective trials.
Children with CHD are at increased risk of developmental disorder or disabilities or developmental delay. Periodic developmental surveillance, screening, evaluation, and reevaluation throughout childhood may enhance identification of significant deficits, allowing for appropriate therapies and education to enhance later academic, behavioral, psychosocial, and adaptive functioning.
No takes yet. Share an insight, caveat, or question.
Marino et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: